We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Cell Lines Available for Research

By Biotechdaily staff writers
Posted on 23 Oct 2005
Nine cell lines are available to commercial and academic researchers worldwide who are seeking a cure for lymphoma, leukemia, pancreatic cancer, or macroglobulinema.

The cell lines were developed by researchers at the Barbara Ann Karmanos Cancer Institute of Wayne State University (Detroit, MI, USA) and are being distributed by Asterand, Inc. (Detroit, MI, USA; www.asterand.com). Asterand also markets breast cancer cell lines under license from the University of Michigan (Ann Arbor, USA) and prostate cancer lines from Onyvax (London, UK). The company acquires donated samples from a world-wide network of collaborating hospitals and clinics.

Following are the cell lines available: Waldenstrom's macroglobulinema, follicular small cleaved cell lymphoma, diffuse large cell lymphoma (chemo-resistant), acute lymphoblastic leukemia (early stage), acute myeloid leukemia, pancreatic cancer, diffuse large cell lymphoma, Burkitt's lymphoma, and nodal histiocytic lymphoma (intermediate grade).

"These cell lines are very good model systems for diseases they are derived from,” said Dr. James Eliason, chief scientific officer of Asterand. "They have been studied extensively by researchers at Wayne State University and elsewhere, which is evident by the fact that there are over 50 publications related to them. In addition to common cancers, these cell lines are great resources for studying rare cancers such as Burkitt's lymphoma, which affects children and young people, aged 12-30, or pancreatic cancer, which is probably one of the most difficult cancers to detect.”




Related Links:
Asterand

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Automatic CLIA Analyzer
Shine i6000
New
Total Laboratory Automation Solution
SATLARS Mini T8

Latest BioResearch News

Study Identifies Protein Changes Driving Immunotherapy Resistance in Multiple Myeloma
23 Oct 2005  |   BioResearch

Genetic Analysis Identifies BRCA-Linked Risks Across Multiple Cancers
23 Oct 2005  |   BioResearch

Study Identifies Hidden B-Cell Mutations in Autoimmune Disease
23 Oct 2005  |   BioResearch